To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
6
University of Connecticut Health Center
Farmington, Connecticut, United States
Hospital Anxiety and Depression Scale
Hospital Anxiety and Depression Scale: This is a validated scale for measuring depression/anxiety symptoms in patients with medical conditions.
Time frame: 12 weeks from baseline
Montgomery-Asberg Depression Rating Scale (MADRS)
Time frame: 12 weeks from baseline
Short Form Health Survey (SF-12)
Time frame: 12 weeks from baseline
Visual Analog Scale for Energy (VAS-E)
Time frame: 12 weeks from baseline
Visual Analog Scale for Pain (VAS-P)
Time frame: 12 weeks from baseline
Leeds Sleep Evaluation Questionnaire (LSEQ)
Time frame: 12 weeks from baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.